These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25637177)

  • 1. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers.
    Levy B; Ramirez N; Novack GD; Kopczynski C
    Am J Ophthalmol; 2015 May; 159(5):980-5.e1. PubMed ID: 25637177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers.
    Kopczynski C; Novack GD; Swearingen D; van Haarlem T
    Br J Ophthalmol; 2013 May; 97(5):567-72. PubMed ID: 23435190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
    Williams RD; Novack GD; van Haarlem T; Kopczynski C;
    Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
    Raber S; Courtney R; Maeda-Chubachi T; Simons BD; Freedman SF; Wirostko B;
    Ophthalmology; 2011 Oct; 118(10):2022-7. PubMed ID: 21788077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    JAMA Ophthalmol; 2013 Oct; 131(10):1288-95. PubMed ID: 23787820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers.
    Tanihara H; Inatani M; Honjo M; Tokushige H; Azuma J; Araie M
    Arch Ophthalmol; 2008 Mar; 126(3):309-15. PubMed ID: 18332309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
    Uusitalo H; Kaarniranta K; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
    Ousler GW; Workman DA; Torkildsen GL
    Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
    Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
    Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
    Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.